secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACHIEVE LIFE SCIENCES, INC. (ACHV)
CIK:        0000949858
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001193125-25-268056
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ACHV Q3 net loss $14.4M; FDA accepts cytisinicline NDA, PDUFA June 20, 2026
---------------------------------------------------------------------------

- Net loss $14.4M for Q3 2025; cash, equivalents & marketable securities $48.1M at Sep 30.
- FDA accepted cytisinicline NDA for smoking cessation; PDUFA target action date June 20, 2026.
- FDA awarded Commissioner’s National Priority Voucher for vaping cessation, enabling 1-2 month expedited review.
- Appointed Erik Atkisson as Chief Legal Officer; over 25 years biopharma legal experience.
- New post hoc data in Thorax shows cytisinicline improved quit rates in adults with COPD.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/949858/000119312525268056/0001193125-25-268056-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/949858/000119312525268056/achv-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-268056

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer